Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831779 · ClinicalTrials.gov registry record · Phase 2
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT00831779 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 116 participants.
The verdict
NCT00831779, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831779
The ClinicalTrials.gov registry entry for NCT00831779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00831779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831779 about?
NCT00831779 is a clinical study titled "Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
What is the current status of trial NCT00831779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2009-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00831779?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00831779?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.